Concepedia

Author

Barry R. Davies

AstraZeneca (United Kingdom)ORCID

Also Known As

B R Davies, B. DAVIES, B. Davies, B. R. Davies, B.R. DAVIES, B.R. Davies, BARRY R. DAVIES, Barry Davies, Barry R Davies, Barry R. Davies

374

Publications

6.9K

Citations

43

H-Index

74

Concepts

All Affiliations

AstraZeneca (United Kingdom)Newcastle UniversityUniversity of LiverpoolAstraZeneca (United States)University of Cambridge
BR

About

Barry R. Davies is an author at AstraZeneca (United Kingdom) specializing in medicine, tumor biology, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

31

2.7K

2

Natural Sciences

3

3

886

3

Health Sciences

2

2

124

4

Public Health

2

2

148

5

Biochemistry

1

1

77

Barry R. Davies

×

74

Publications

6.2K

Citations

40

H-Index

YearCitations

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson,

Cancer Research

2009

790

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley,

Molecular Cancer Therapeutics

2012

453

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logié, Jennifer S. McKay,

Molecular Cancer Therapeutics

2007

387

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada,

Nature Communications

2019

327

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker,

Molecular Oncology

2009

254

Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1.

Barry R. Davies, Michael P.A. Davies, Fiona E. M. Gibbs,

PubMed

1993

253

Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer Progression <i>In Vivo</i>

Christian Thomas, François Lamoureux, Claire Crafter,

Molecular Cancer Therapeutics

2013

150

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo,

Clinical Cancer Research

2017

139

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard, Jon Curwen, Teeru Bihani,

Molecular Cancer Therapeutics

2015

125

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

Dominika Ewelina Butler, Christopher R. Marlein, Hannah F. Walker,

Oncotarget

2017

123

Page 1